Skip to main content
SpringerLink
Log in

Soins palliatifs: peut-on parler de qualité de vie en phase métastatique?

  • Chapter
Cancer du sein avancé

Abstrait

Poser la question sous cette forme paraît impliquer une réponse évidente. L’amélioration de la qualité de vie est un objectif premier de l’activité médicale, quelle qu’en soit sa situation: prévention, dépistage, thérapeutique adjuvante ou palliative; le patient doit pouvoir espérer, sinon tirer, un bénéfice du geste entrepris. L’évaluation des avantages, quels qu’ils soient, doit être contrebalancée par celle des inconvénients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Wood WC, Muss HB, Solin LJ, Olopade OI (2005) Malignant tumors of the breast. In: De Vita VT, Hellman S, Rosenberg SA. Cancer. Principles and Practice of Oncology. Lippincot Williams and Wilkins: 169–231

    Google Scholar 

  2. Krakowski I, Boureau F, Bugat R et al. (2004) Pour une coordination des soins de support pour les personnes atteintes de maladies graves: proposition d’organisation dans les établissements de soins publics et privés. Oncologie 6: 7–15.

    Article  Google Scholar 

  3. Von Minckwitz G, for The Breast Commission of the German Gynaecological Oncology Working Group (2006) Evidence-based treatment of metastatic breast cancer-2006 recommendations by the AGO Breast Commission. Eur J Cancer 2897–908

    Google Scholar 

  4. Beslija S, Bonneterre J, Burstein H et al. (2006) Second consensus on medical treatment of metastatic breast cancer. Ann. Oncol 18: 215–25

    Article  PubMed  Google Scholar 

  5. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force (2007) Metastatic breast cancer. The Breast 16: 9–10

    Article  Google Scholar 

  6. Smith I (2006) Goals of treatment for patients with metastatic breast cancer. Sem Oncol 33: S2–S5

    Article  Google Scholar 

  7. Zittoun R. Dictionnaire de cancers de A à Z, FNCLCC. Qualité de vie. http://www.fnclcc.fr/fr/patients/dico/alpha.php

    Google Scholar 

  8. ASCO (1996) Outcomes of cancer treatment for technology assessment and cancer tratment guidelines. J Clin Oncol 14: 671–9

    Google Scholar 

  9. Conroy T (2006) La qualité de vie: un élément dans l’élaboration de la stratégie thérapeutique? Oncologie 8: 477–82

    Article  Google Scholar 

  10. Marino P, Moatti JP (2006) Mesurer la qualité de vie: une nécessité en thérapeutique cancérologie. Oncologie 8: 454–9

    Article  Google Scholar 

  11. Buron C, Livartowski A (2006) Prise en compte simultanée de la qualité de vie et de la quantité de vie: application à la cancérologie. Oncologie 8: 483–8

    Article  Google Scholar 

  12. Mackey JR, Mastro L, Sormani MP et al. (2006) Trastuzumab prolongs progression — free survival in hormone — independent and HER2 — positive metastatic breast cancer. Breast Cancer Res Treat 100Suppl. 1: S5

    Google Scholar 

  13. Pierga JY, Robain M, Jouve M et al. (2001) Response to chemotherapy is a very major parameter — influencing long-term survival of metastatic breast cancer patients. Ann Oncol 12: 231–7

    Article  PubMed  CAS  Google Scholar 

  14. Bruzzi P, Del Mastro L, Sorani MP et al. (2005) Objective response to chemotherapy as a potential surrogate end point of survival metastatic breast cancer patients. J Clin. Oncol. 23: 5117–25

    Article  PubMed  Google Scholar 

  15. Geels P, Eisenhauer E, Bezjak A et al. (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18: 2395–405

    PubMed  CAS  Google Scholar 

  16. Sledge GW, Neuberg D, Bernardo P et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588–92

    Article  PubMed  Google Scholar 

  17. Seidman AD (2003) Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism? (Editorial) J Clin Oncol 21: 577–9

    Article  PubMed  Google Scholar 

  18. Overmeyer B (2003) Combination chemotherapy for metastatic breast cancer: reaching for the cure. (Editorial). J Clin Oncol 21: 580–2

    Article  Google Scholar 

  19. Stadtmauer EA, O’Neil A, Goldstein LJ et al. (2000) Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoïetic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342: 1069–76

    Article  PubMed  CAS  Google Scholar 

  20. McQuellon RP, Muss HB, Hoffman SL et al. (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 13: 858–68

    PubMed  CAS  Google Scholar 

  21. Nooij MA, De Haes JC, Beex LV et al. (2003) Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists’ preferences. Eur J Cancer 39: 614–21

    Article  PubMed  CAS  Google Scholar 

  22. Brun B, Benchalal M, Lebas C et al. (1997) Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment. Cancer 79: 2137–46

    Article  PubMed  CAS  Google Scholar 

  23. Modi S, Seidman A (2005) Combination versus sequentiel single-agent therapy for the treatment of metastatic breast cancer. Eur J Cancer Suppl 3: 3–8

    Article  CAS  Google Scholar 

  24. Porkka K, Blomquvist C, Rissanen P et al. (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12: 1639–47

    PubMed  CAS  Google Scholar 

  25. Cardoso F, Di Leo A, Lohrisch C et al. (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197–207

    Article  PubMed  CAS  Google Scholar 

  26. Bouleuc C, Copel L (2007) Les aspects cliniques, éthiques et relationnels de l’arrêt de la chimiothérapie. Réflexions Med Oncol 17: 39–43

    Google Scholar 

  27. Aubry R, d’Herouville D et al. (2005) Soins palliatifs et soins de support. Oncologie 7: 203–8

    Article  Google Scholar 

  28. Baines M (1994) Le concept de douleur globale. In: Saunders C, ed. Soins palliatifs, une approche pluridisciplinaire. Paris, Lamarre, coll Infirmière, société et avenir

    Google Scholar 

  29. Molassiotis A, Scott J et al. (2006) Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14: 260–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre Eugène Marquis, Université de Rennes I, Rue de la bataille Flandres-Dunkerque CS 44229, 35442, Rennes cedex

    P. Kerbrat & E. Botton

Authors
  1. P. Kerbrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Botton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Kerbrat, P., Botton, E. (2007). Soins palliatifs: peut-on parler de qualité de vie en phase métastatique?. In: Cancer du sein avancé. Springer, Paris. https://doi.org/10.1007/978-2-287-72615-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72615-6_18

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72614-9

  • Online ISBN: 978-2-287-72615-6

Publish with us

Policies and ethics

Search

Navigation